Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Stride Arcolab September quarter net sales are expected to go up by 27.1% at Rs 547 crore, year-on-year, (YoY) basis.
The company's net profit (excluding any exceptional gains/losses) is expected to go up 86.6% at Rs 30.5 crore on YoY basis.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
